A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis

International Braz J Urol

Volumn 43, Issue 1, 2017, Pages 134-141

  Tutolo, Manuela ^a   Ammirati, Enrico ^b   Castagna, Giulia ^c   Klockaerts, Katrien ^d   Plancke, Hendrik ^e   Ost, Dieter ^f   van der Aa, Frank ^a   Ridder, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MOLINETTE HOSPITAL   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Algemeen Ziekenhuis Sint Lucas Gent   (Belgium)

^e IMELDA HOSPITAL   (Belgium)

^f St Blasius Hospital   (Belgium)

Author keywords

Chondroitin Sulfates; Cystitis; Dimethyl Sulfoxide; Interstitial

Indexed keywords

CHONDROITIN SULFATE; DIMETHYL SULFOXIDE; URINARY TRACT AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS, INTERSTITIAL; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MICTURITION; MIDDLE AGED; MULTICENTER STUDY; PAIN MEASUREMENT; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; AGED; CHONDROITIN SULFATES; CYSTITIS, INTERSTITIAL; DIMETHYL SULFOXIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; URINATION; UROLOGICAL AGENTS; YOUNG ADULT;

EID: 85013151307     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2016.0302     Document Type: Article

References (31)

1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60-7.
2. Hanno P, Nordling J, Fall M. Bladder pain syndrome. Med Clin North Am. 2011;95:55-73.
3. Nordling J, Fall M, Hanno P. Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol. 2012;30:457-64.
4. Engeler DS, Baranowski AP, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64:431-9.
5. Hanno PM, Erickson D, Moldwin R, Faraday MM; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545-53.
6. Daha LK, Lazar D, Simak R, Pflüger H. The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome/interstitial cystitis: preliminary results. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:987-90.
7. Daha LK, Riedl CR, Lazar D, Simak R, Pflüger H. Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol Nephrol. 2008;42:369-72.
8. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:717-21.
9. Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140:36-9.
10. D. Engeler, A.P. Baranowski, J. Borovicka, A. Cottrell, P. Dinis-Oliveira, S. Elneil, J. Hughes, E.J. Messelink, A. vanOphoven, Y. Reisman, A.C. de C Williams, EAU Guidelines on Chronic Pelvic Pain, Available from: http://uroweb.org/guideline/chronic-pelvic-pain//
11. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103:56-60.
12. Nordling J, van Ophoven A. Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung. 2008;58:328-35.
13. Gauruder-Burmester A, Popken G. [Follow-up at 24 months after treatment of overactive bladder with 0.2 % sodium chondroitin sulfate]. Aktuelle Urol. 2009;40:355-9.
14. Baranowski AP, Abrams P, Berger RE, Buffington CA, de C Williams AC, Hanno P, et al. Urogenital pain--time to accept a new approach to phenotyping and, as a consequence, management. Eur Urol. 2008;53:33-6.
15. Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103:910-8.
16. Nickel JC, Egerdie RB, SteinhoffG, Palmer B, Hanno P. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology. 2010;76:804-9.
17. Nickel JC, Hanno P, Kumar K, Thomas H. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79:1220-4.
18. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657-61.
19. O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58-63.
20. Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert Opin Investig Drugs. 2014;23:751-7.
21. Sorensen RB. Chondroïtin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol Suppl. 2003;2:16-8.
22. SteinhoffG, Ittah B, Rowan S. The efficacy of intravesicular sterile sodium chondroitin sulfate 0.2% in potassium tested positive patients with interstitial cystitis. Adv Exp Med Biol. 2003;539:731-9.
23. Thakkinstian A, Nickel JC. Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) metaanalytical approach. Can Urol Assoc J. 2013;7:195-200.
24. Peeker R, Haghsheno MA, Holmäng S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164:1912-5.
25. Dawson TE, Jamison J. Intravesical treatments for painful bladder syndrome/interstitial cystitis. Cochrane Database Syst Rev. 2007;4:CD006113.
26. NICe advice on Interstitial cystitis: dimethyl sulfoxide bladder Instillation, available at. https://www.nice.org.uk/guidance/esuom26/resources/interstitial-cystitis-dimethyl-sulfoxidebladder-instillation-54116459004935365
27. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162-70.
28. Rössberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol. 2005;39:73-7.
29. Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Transl Androl Urol. 2015;4:600-4.
30. Downey A, Hennessy DB, Curry D, Cartwright C, Downey P, Pahuja A. Intravesical chondroitin sulphate for interstitial cystitis/painful bladder syndrome. Ulster Med J. 2015;84:161-3.
31. Nickel JC, Shoskes D, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol. 2009;182:155-60.